explore -WSS

explore

author：knowledge 2025-09-03 03:31:55 - browse：526

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA does about

hotspot

WSS

Covid isolation guidance eased by the CDC

Sanofi CEO defends move to abandon profit guidance, boost research

House looks to weaken Medicare negotiation

FDA approves Recor Medical high blood pressure device

Scientists unlock the key to scar

MoonLake credibility takes another hit with mid

knowledge

explore

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A clever new way to fix Medicaid and graduate medical education

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kenai launches with $82 million for Parkinson’s stem cell therapy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House calls on federal agencies to crack down on AI abuses

Medicare details structure of new drug price negotiation program

The Sacklers, horror, and ‘The Fall of the House of Usher’

Novavax promises a turnaround & Lilly roils the obesity market

Flu vaccine offering decent levels of protection this winter, new data show

leisure time

Abortion clinic in Cancun will cater to Americans

Medicare solvency divides Republicans at the presidential debate

FDA approves potent Eli Lilly obesity drug, Zepbound

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Biotech incubator Curie.Bio graduates its first startup

How to fix the rural physician shortage in the U.S.

hotspot

Wikipedia

knowledge

entertainment